Advertisement

Picture [iito] Made Without Love 650x80px

News > All

Total search results: 9827 | Ordered by Source (descending)
next pagenext page 1 2 3 ... 97 98 99

order ascendingorder descendingSource order ascendingorder descendingDate
4SC AG. (11/6/14). "Press Release: 4SC Announces Financial Results for the First Nine Months and the Third Quarter of 2014". Planegg-Martinsried. 2014-11-06
4SC AG. (11/4/13). "Press Release: AiCuris, 4SC Discovery and Crelux Announce Drug Discovery Collaboration". Planegg-Martinsried & Wuppertal. 2013-11-04
4SC AG. (11/4/10). "Press Release: 4SC’s Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial. Vidofludimus Generates a Response Rate of 88.5% for the Treatment of Patients with Crohn’s Disease and Ulcerative Colitis". Planegg-Ma 2010-11-04
4SC AG. (11/16/10). "Press Release: 4SC to Highlight the Potential of Its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium »on Molecular Targets and Cancer Therapeutics«". Planegg-Martinsried. 2010-11-16
4SC AG. (11/12/19). "Press Release: 4SC AG Secures circa EUR 22.4 Million from a Capital Increase [Not for release in US, Australia, Canada, et al.]". Planegg-Martinsried. 2019-11-12
4SC AG. (11/11/10). "Press Release: 4SC Reports First Nine Months Financial Results 2010". Planegg-Martinsried. 2010-11-11
4SC AG. (10/26/17). "Press Release: 4SC Provides Q3 and 9M 2017 Update". Planegg-Martinsried. 2017-10-26
4SC AG. (10/26/10). "Press Release: 4SC Announces Initial Phase II Data from the SAPHIRE Study with Resminostat at the 8th International Symposium on Hodgkin Lymphoma". Planegg-Martinsried. 2010-10-26
4SC AG. (10/23/12). "Press Release: 4SC Discovery Receives Research Grant of EUR 600,000 for Development of Personalised Cancer Drugs". Planegg-Martinsried. 2012-10-23
4SC AG. (10/21/16). "Press Release: Dr Daniel Vitt to Step Down as CDO/CSO and from the Management Board at the End of 2016". Planegg-Martinsried. 2016-10-21
4SC AG. (10/10/17). "Press Release: Resminostat Demonstrates Potential to Significantly Alleviate Itching in CTCL Patients". Planegg-Martinsried. 2017-10-10
4SC AG. (10/1/12). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in China". Planegg-Martinsried. 2012-10-01
4SC AG. (1/8/13). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in Europe". Planegg-Martinsried. 2013-01-08
4SC AG. (1/7/11). "Press Release: 4SC Announces First-in-Man Phase I Results for 4SC-203". Planegg-Martinsried. 2011-01-07
4SC AG. (1/23/15). "Press Release: 4SC AG Plans Extraordinary General Meeting and Reduction of Share Capital". Planegg-Martinsried. 2015-01-23
4SC AG. (1/21/11). "Press Release: 4SC Presents Update on Phase II SHELTER Trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium". Planegg-Martinsried. 2011-01-21
4SC AG. (1/20/11). "Press Release: 4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-mutant Colorectal Cancer Patients with Resminostat". Planegg-Martinsried. 2011-01-20
4SC AG. (1/19/12). "Press Release: 4SC’s Cancer Compound Resminostat Meets Primary Endpoint in Phase II Trial in Advanced Liver Cancer (HCC) ahead of Schedule". Planegg-Martinsried. 2012-01-19
4SC AG. (1/13/15). "Press Release: Beyond Research Initiative of 4SC Discovery and Crelux Reaches First Milestone in Drug Discovery Project for Helmholtz Zentrum München". Planegg-Martinsried & Munich. 2015-01-13
4SC AG. (1/12/15). "Press Release: Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join the Supervisory Board of 4SC AG". Planegg-Martinsried. 2015-01-12
4DCell Fate Project. (2/13/12). "Press Release: Cell Fate in 4D. Bringing together European Excellence to Uncover the Mechanisms at Work that Determine Cell Fate". Barcelona. 2012-02-13
4D Molecular Therapeutics. (4/30/18). "Press Release: 4DMT and Roche Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products". Emeryville, CA. 2018-04-30
4-Antibody AG. (9/19/11). "Press Release: 4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration". Basel. 2011-09-19
4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel. 2011-08-16
4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel. 2012-10-08
4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY. 2013-01-29
3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris. 2018-11-20
next pagenext page 1 2 3 ... 97 98 99



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top